bpc-157 fda approval status safety commitee votes 8-6 to make legal. What the FDA briefing report said about the evidence bpc 157 fda status bpc-157

Common Protocol: MK-677: 12.525 mg daily, oral, taken at night BPC-157: 250500 mcg daily, subcutaneous Cycle: 812 weeks for MK-677

An immunodominant NP105113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Commonly Reported Side Effects Based on community reports, side effects appear relatively uncommon and typically mild: Most Frequently Reported: Injection site reactions (redness, minor pain, itching) Mild nausea (particularly with oral administration) Temporary dizziness Headache Fatigue Less Commonly Reported: Skin flushing Changes in appetite Temporary mood changes Vivid dreams Theoretical Concerns Growth Factor Effects: BPC-157's upregulation of growth factors raises theoretical concerns for: Cancer promotion in those with existing malignancies Acceleration of undiagnosed tumors Effects on benign growths (polyps, fibroids) No evidence directly supports these concerns, but caution is warranted given the mechanisms involved

18,26 Figure 2 Evaluation of Suspected Vitamin B12 Deficiency Treatment Vitamin B 12 deficiency can be treated with intramuscular injections of cyanocobalamin or oral vitamin B 12 therapy